Teva and APP Announce Launch of Generic Gemzar

Teva Pharmaceutical Industries Ltd. TEVA and APP Pharmaceuticals, Inc. announced today the commercial launch of Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials, the generic version of Gemzar, in the United States, pursuant to a commercialization, manufacture and supply agreement signed by the two companies. Annual sales of Eli Lilly LLY and Company's Gemzar® were approximately $785 million in the United States in 2010, based on IMS sales data.